Nanolynx Biologics

Startup

Nanolynx Biologics is a platform-to-pipeline biotech company developing first-in-class conditionally active nanobody-drug conjugates (CA-NDCs) designed for tumor-selective activation, deep tissue penetration, and reduced systemic toxicity. Powered by our proprietary IntelliBody™ platform, we overcome the key biological and safety limitations of conventional ADCs. We are building a scalable CA-NDC pipeline in high-unmet-need solid tumors where existing ADCs are constrained by poor tissue penetration and narrow therapeutic windows.

website